It is necessary to identify alternative cell signaling pathways that might be involved in the pathogenesis of MPN mutant clones, and this could be targeted alone or in combination with JAK/STAT for improved therapeutic benefit [67,87,88]. Here, SOAT1 is linked to myeloproliferative disorder.